HANSOH PHARMA PRESENTED DATA FROM TWO CLINICALSTUDIES OF HS-10382, A NOVEL BCR..ABL1 ALLOSTERIC INHIBITOR, IN CHRONIC MYELOID LEUKEMIA (CML) ... carrying BCR..ABL1 fusion mutations or point mutations.
) ... The reader should not assume that the information is accurate and complete ... Washington, D.C ...BCR Wealth Strategies, LLC ... BCR Wealth Strategies LLC published this content on May 01, 2026, and is solely responsible for the information contained herein.
Terns' lead candidate TERN-701 is an investigational oral allosteric BCR..ABL1 tyrosine ... "The first approval of a BCR..ABL1 tyrosine kinase inhibitor 25 years ago transformed the prognosis for many patients with chronic myeloid leukemia.